Caprock Group LLC lifted its position in shares of Novartis AG (NYSE:NVS – Free Report) by 96.5% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 32,889 shares of the company’s stock after purchasing an additional 16,153 shares during the quarter. Caprock Group LLC’s holdings in Novartis were worth $3,501,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the company. Private Ocean LLC bought a new stake in Novartis in the first quarter worth approximately $25,000. Frazier Financial Advisors LLC acquired a new stake in shares of Novartis during the 4th quarter worth approximately $26,000. Richardson Financial Services Inc. bought a new stake in shares of Novartis in the 4th quarter valued at $26,000. Clearstead Trust LLC lifted its position in shares of Novartis by 73.5% during the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock valued at $26,000 after acquiring an additional 114 shares during the period. Finally, New Millennium Group LLC bought a new position in Novartis during the second quarter worth $28,000. Institutional investors own 13.12% of the company’s stock.
Novartis Trading Up 0.1 %
NYSE:NVS opened at $116.65 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. Novartis AG has a one year low of $92.19 and a one year high of $120.92. The company has a market cap of $238.43 billion, a PE ratio of 15.74, a PEG ratio of 1.74 and a beta of 0.57. The firm has a 50-day moving average of $112.66 and a 200-day moving average of $104.52.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the stock. Barclays raised shares of Novartis to a “strong sell” rating in a research note on Monday, June 24th. Jefferies Financial Group downgraded Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $121.00 price objective (up previously from $119.00) on shares of Novartis in a research note on Thursday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, Novartis has an average rating of “Hold” and an average price target of $118.38.
View Our Latest Research Report on NVS
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
See Also
- Five stocks we like better than Novartis
- What Are Trending Stocks? Trending Stocks Explained
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- What Does a Stock Split Mean?
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.